The Rg3 capsule is the first new anti-cancer single Chinese herb medicine produced and licensed under the permission of the SFDA. The only active ingredient is the Ginseng RG3 molecule and has a purity of over 95%. It has a molecular weight of 784 Daltons and a structure as below:

 Rg₃ molecule

The Japanese scientist, Beichuanxun, identified the structure in the 1980’s and in 1993 it was discovered that Rg₃ has selectivity to inhibit the perfusion and transforming cancer cells. Shinkai has proved that Rg₃ has a significant inhibitory function in the mouse hepatoma cancer cell, MM1, B16FE7, black pigmented cancer cell, cellular pulmonary cancer OC-10 and edinocarcenoma PSN-1. These cancers previously mentioned mainly operate on the monolayer mesentery cells by adhering to them. Kim also discovered that RG₃ has inhibitory effects on the aortal endothelial cells Ca2+ inflow, the inflowing Ca2+ can cause endothelial cell relaxation. In this way the perfusion of cancer cells is restrained. For twenty years the scientists in Japan, America, Russia and France have carried out extensive research but due to the very small quantities of RG₃ contained in ginseng, only 0.003%. The extraction equipment is very complicated and expensive; it could not previously be achieved on an industrial scale for clinical use. The two Chinese specialists, Dr Fu Li and Dr Lu Qi are the first inventors of special processing equipment required to obtain RG₃ in quantity. They achieved high purity and industrialization of the RG₃ extraction process. They also carried out detailed systematic research on the pharmacological mechanisms of the RG₃ action as well as extensive clinical research.

Yatai has proved that RG₃ has good effect on the inhibition of cancer cell growth and also inhibits the transformation of the cancer cells. For B-16 ‘Black pigmented cancer?and S-100 ‘Neoplastic cancer? the inhibition rate is up to 60%. For B-16 ‘Black pigmented cancer?the practical lung transforming character and spontaneous lung transforming cancer shows an inhibitory rate of 70-80%. The initial research on the theoretical functional mechanism has shown RG₃ inhibited Karyokinisis (mitosis). A reduction in the prophase of the protein synthesis reduces the growth rate of the cancer. Simultaneously it induces the death of the cancer cell. The RG₃ can inhibit the cancer cell adhered to the fabric conglutination protein and the layer conglutination protein. It can destroy the cancer cell and also prevent the cancer cell embedding into the surface of the blood vessel and cause more perfusion of the epithelial basement layers of the blood vessels. Through the restraint of the growth factor of the fabric cell of alkaline (bFGF) and the promotion of epithelial growth factor for the blood vessel, (VEGF). (Vascular endothelial cell growth factor). The gene expression of (bFGFR) inhibits or restrains the proliferation of epithelial cells and the new blood vessels forming the antiogenesis in the cancer. In this way and all the previously mentioned mechanisms inhibit the growth, transforming functions and perfusion of the cancer.

With the permission of the SFDA, from May 1998 to April 1999 The National Traditional Chinese Medical Research Institute of Guang An Men Hospital took the lead role in the new drug investigation process and carried out the II and III stage clinical trials according to these standards. The experimental cases included non-small cell type of pulmonary cancer, hepatoma, gastric cancer, breast cancer. The result of the investigation showed RG₃ co-operates with chemotherapy. The efficiency of the treatment is raised from 12.9% to 33.3% also it reduces and relieves the side-effects, significantly improved the clinical syndromes and the life quality of the patients.

RG₃ is purified from extracted ginseng sapoinin derived from the first grade ginseng root. It is the first grade first traditional Chinese medicine for cancer treatment in China that is licensed under SFDA permission. This took place in January 2000. It is also the first product identified which has angiogenic properties and it has very obvious and strong mechanisms for its function in inhibiting cancer.

Yatai has researched and developed the product, thus owning the intellectual property rights and Patent.

The purity of the active molecule is over 95%. The efficiency of inhibition for many types of high rate transferring cancer and the perfusion growth is over 60%. The inhibition of the cancer transferring to the lung and liver are between 70-80%. It has very good effects on both inhibition and transfer of cancer.

There is a wide range of successful clinical applications for RG₃ and this will lead to a bright future for the product. Currently being used in over 300 major medical centre and is well placed to widen its use.

[ Home ] [ Up ]      

Send mail to webmaster@yatai.com with questions or comments about this web site.
Copyright ?2004 Jilin Yatai (Group) Co., Ltd.
Last modified: Sunday, 19. December 2004